ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,246.95
0.18%
Dow Jones
38,807.33
0.25%
Gold vs US Dollar
2,363.95
0.38%
Brent Oil
78.695
0.17%
Bitcoin
71,170.53
0.13%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Revance Therapeutics Inc (RVNC) Share Price

RVNC Revance Therapeutics Inc

3.06
0.15 (5.15%)
06 Jun 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Revance Therapeutics Inc NASDAQ:RVNC NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.15 5.15 3.06 2.95 3.06 3.135 2.8811 2.93 1,597,428 23:45:50   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 234.04M -323.99M -3.6727 -0.83 267.29M
 Type  Size  Price  Time  Units 
 20 366 3.06 23:45:58 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore RVNC News
28/05/202421:05BWRevance to Participate in Upcoming Investor Conferences
09/05/202421:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/05/202421:08EDGAR2Form 8-K - Current report
09/05/202421:06BWRevance Reports First Quarter 2024 Financial Results, Provides Corporate Update
09/05/202421:05BWRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
02/05/202421:05BWRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
12/04/202413:00BWRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Period
Draw mode
Data Downloads for RVNC

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Revance Therapeutics Inc Articles